Trials / Completed

CompletedNCT00503360

Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension

A Multicenter, Randomized, Placebo-Controlled, Double-Masked, 4-Arm Parallel Group Study to Assess the Tolerability, Safety and Efficacy of Two Doses of SAD448 in Subjects With Ocular Hypertension

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 80 (estimated)

Sponsor: Novartis · Industry
Sex: All
Age: 18 Years – 65 Years
Healthy volunteers: —

Summary

This study will evaluate the tolerability and safety of SAD448 and explore the compound's effect on intraocular pressure in subjects with ocular hypertension.

Conditions

Ocular Hypertension

Interventions

Type	Name	Description
DRUG	SAD448

Timeline

Start date: 2007-04-01
First posted: 2007-07-18
Last updated: 2008-04-24

Locations

1 site across 1 country: Australia

Source: ClinicalTrials.gov record NCT00503360. Inclusion in this directory is not an endorsement.